Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Chevalier

Showing results (181-190 of 201) with videos related to

Pageof 21
Sort By:
JACC. Cardiovascular Interventions|July 25, 2015
Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic StentYuki Ishibashi, Takashi Muramatsu, Shimpei Nakatani, et al.
Radiology|January 8, 2025
Prognostic Value of Cardiac MRI Late Gadolinium Enhancement Granularity in Participants with Ischemic CardiomyopathyAlexandre Unger, Jérôme Garot, Solenn Toupin, et al.
Journal of the American College of Cardiology|July 9, 2011
6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mmRoberto Diletti, Yoshinobu Onuma, Vasim Farooq, et al.
Circulation. Cardiovascular Interventions|July 13, 2026
Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT TrialBernard Chevalier, Davide Cao, Pieter C Smits, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 24, 2018
The incidence and relevance of site-reported vs. patient-reported angina: insights from the ABSORB II randomized trial comparing Absorb everolimus-eluting bioresorbable scaffold with XIENCE everolimus-eluting metallic stentMaik J Grundeken, Roseann M White, John B Hernandez, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 1, 2013
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trialsBill D Gogas, Christos V Bourantas, Hector M Garcia-Garcia, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 16, 2026
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trialPieter C Smits, Adrian Włodarczak, Bernard Chevalier, et al.
Journal of the American College of Cardiology|August 18, 2022
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet TherapyMarco Valgimigli, Enrico Frigoli, Pascal Vranckx, et al.
JACC. Cardiovascular Interventions|June 23, 2012
Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trialBill D Gogas, Patrick W Serruys, Roberto Diletti, et al.
Heart (British Cardiac Society)|November 3, 2012
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trialRoberto Diletti, Vasim Farooq, Chrysafios Girasis, et al.
Pageof 21

Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
JACC. Cardiovascular Interventions|July 25, 2015
Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic StentYuki Ishibashi, Takashi Muramatsu, Shimpei Nakatani, et al.
Radiology|January 8, 2025
Prognostic Value of Cardiac MRI Late Gadolinium Enhancement Granularity in Participants with Ischemic CardiomyopathyAlexandre Unger, Jérôme Garot, Solenn Toupin, et al.
Journal of the American College of Cardiology|July 9, 2011
6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mmRoberto Diletti, Yoshinobu Onuma, Vasim Farooq, et al.
Circulation. Cardiovascular Interventions|July 13, 2026
Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT TrialBernard Chevalier, Davide Cao, Pieter C Smits, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 24, 2018
The incidence and relevance of site-reported vs. patient-reported angina: insights from the ABSORB II randomized trial comparing Absorb everolimus-eluting bioresorbable scaffold with XIENCE everolimus-eluting metallic stentMaik J Grundeken, Roseann M White, John B Hernandez, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 1, 2013
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trialsBill D Gogas, Christos V Bourantas, Hector M Garcia-Garcia, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 16, 2026
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trialPieter C Smits, Adrian Włodarczak, Bernard Chevalier, et al.
Journal of the American College of Cardiology|August 18, 2022
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet TherapyMarco Valgimigli, Enrico Frigoli, Pascal Vranckx, et al.
JACC. Cardiovascular Interventions|June 23, 2012
Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trialBill D Gogas, Patrick W Serruys, Roberto Diletti, et al.
Heart (British Cardiac Society)|November 3, 2012
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trialRoberto Diletti, Vasim Farooq, Chrysafios Girasis, et al.
Pageof 21